EMEA dismisses Gardasil risks
This article was originally published in Scrip
The EU's CHMP has concluded that the serious adverse events suffered by two girls in Spain after vaccination with Sanofi Pasteur MSD's Gardasil (human papillomavirus vaccine) are unlikely to be related to the vaccine. The European Medicines Agency says the benefits of Gardasil continue to outweigh its risks and it recommends that vaccination continue through national programmes.
You may also be interested in...
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.